ONXEO (EPA:ALONX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ONXEO

PRESS RELEASE

published on 10/30/2025 at 09:05, 1 month 5 days ago

Half-Year Financial Report 2025
BRIEF

published on 10/30/2025 at 09:03, 1 month 5 days ago

Valerio Therapeutics' financial and strategic review for the first half of 2025

Strategic Refocusing Valerio Therapeutics 2025 Financial Results V-Body Platforms Seeking Partnerships
PRESS RELEASE

published on 10/30/2025 at 09:00, 1 month 5 days ago

Press Release Publication Half-Year Financial Report 2025
Valerio Therapeutics S.A. announces first-half 2025 financial results, discontinuation of clinical activities, and strategic refocus on preclinical R&D. Strengthened financial structure through shareholder advances and capital increases

Financial Results Valerio Therapeutics First-half 2025 Preclinical R&D Shareholder Advances
BRIEF

published on 03/19/2025 at 15:32, 8 months 16 days ago

Valerio Therapeutics Announces Board Members and Their Roles

Board Members Valerio Therapeutics Corporate Roles Paris-based Company Executive Responsibilities
PRESS RELEASE

published on 03/19/2025 at 15:27, 8 months 16 days ago

Inside Information / Other news releases
Valerio Therapeutics announces new board members and their positions in other companies as of March 19, 2025

Board Members Positions Valerio Therapeutics Other Companies March 19 2025
BRIEF

published on 03/19/2025 at 12:35, 8 months 16 days ago

Valerio Therapeutics Board Meeting Decisions

Director Changes Shareholder Meeting Share Split Board Resolutions Article Amendments
PRESS RELEASE

published on 03/19/2025 at 12:30, 8 months 16 days ago

Inside Information / Other news releases
Valerio Therapeutics Board of Directors convenes a General Meeting with resolutions on director dismissals, co-optation, share division, bylaws amendment, and formalities powers

Board Of Directors General Meeting Resolutions Valerio Therapeutics Share Division
BRIEF

published on 02/04/2025 at 10:40, 10 months ago

Valerio Therapeutics opts for strategic refocusing

Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
PRESS RELEASE

published on 02/04/2025 at 10:35, 10 months ago

Inside Information / Other news releases
Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development

Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
BRIEF

published on 10/01/2024 at 00:56, 1 year 2 months ago

Valerio Therapeutics Reports First Half 2024 Financial Results

Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 32 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 37 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 7 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 2 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 7 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 37 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 17 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 42 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 52 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 57 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 7 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 22 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE